Optellum announced October 20 that its lung cancer risk stratification software is now integrated into RapidAI’s enterprise platform, expanding access to what the company describes as the world’s first FDA-cleared and Medicare-reimbursed AI solution for image-based lung cancer risk assessment, a combination of regulatory clearance and payer coverage that remains rare among medical AI tools.
Why Lung Nodule Risk Assessment Is Such a Hard Clinical Problem
Lung nodules detected incidentally on CT scans present a persistent diagnostic dilemma: the vast majority are benign, but a meaningful minority represent early-stage lung cancer, and distinguishing between the two historically required either invasive biopsy, repeated follow-up imaging over months to track growth, or clinical judgment based on nodule size and shape that leaves considerable uncertainty. Optellum’s software analyzes CT imaging data to generate a quantitative malignancy risk score intended to help physicians decide more confidently between immediate intervention, continued monitoring, or ruling out further workup.
Why Medicare Reimbursement Is the Bigger Milestone
FDA clearance alone does not guarantee a medical AI tool gets used, since hospitals and physicians often hesitate to adopt tools that create additional costs without a corresponding reimbursement pathway. Medicare reimbursement for image-based lung cancer risk stratification signals that federal health regulators have judged the tool’s value substantial enough to justify payment, a milestone that could meaningfully accelerate adoption compared to the many FDA-cleared AI tools that lack any dedicated reimbursement code and are instead absorbed as an unreimbursed cost by hospital radiology departments.
What Integration Into RapidAI Actually Changes
RapidAI’s platform is already used widely in stroke and vascular imaging workflows across many hospital systems, meaning Optellum’s integration gives its lung-nodule tool a distribution channel into facilities that may already have RapidAI infrastructure installed for other clinical uses, lowering the technical and procurement barriers to adoption compared to a standalone deployment. This kind of platform consolidation reflects a broader trend in medical AI, where smaller specialized AI developers increasingly partner with larger imaging-platform companies rather than building independent hospital sales and integration teams from scratch.
The Broader Lung Cancer Screening Context
Lung cancer screening guidelines in the US currently recommend annual low-dose CT screening for a defined high-risk population based on age and smoking history, a program that has historically suffered from relatively low participation rates compared to screening for other major cancers. Tools like Optellum’s, by making incidental and screening-detected nodules easier to triage confidently, could help address physician hesitancy that sometimes contributes to delayed follow-up on suspicious imaging findings.
What Critics Want to See Next
As with other AI diagnostic tools, researchers studying real-world AI adoption in oncology emphasize that reimbursement and clearance address access barriers but do not themselves prove the tool improves patient outcomes at scale, underscoring the need for continued post-market surveillance data showing the tool’s risk scores translate into appropriately earlier cancer detection or fewer unnecessary invasive procedures. Optellum has pointed to its existing clinical validation studies as evidence of accuracy, though broader real-world outcomes data across diverse hospital settings will strengthen the case further.
What’s Next
Watch for adoption data showing how many hospital systems with existing RapidAI infrastructure actually activate the lung cancer risk tool following this integration, and for any updated Medicare reimbursement policy that could extend similar coverage to competing lung-nodule AI tools. The outcome could help establish a template other cancer-imaging AI developers pursue to clear the reimbursement hurdle that has limited broader clinical AI adoption.
Photo: Anna Shvets / PEXELS via Pexels
